7-Hydroxycarbostyril
CAS No. 70500-72-0
7-Hydroxycarbostyril( 3,4-Dihydro-7-hydroxycarbostyril )
Catalog No. M27524 CAS No. 70500-72-0
7-Hydroxycarbostyril (3,4-Dihydro-7-hydroxycarbostyril) is a kind of pharmaceutical intermediate.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 46 | In Stock |
|
| 25MG | 70 | In Stock |
|
| 50MG | 106 | In Stock |
|
| 100MG | 158 | In Stock |
|
| 200MG | 239 | In Stock |
|
| 500MG | 357 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name7-Hydroxycarbostyril
-
NoteResearch use only, not for human use.
-
Brief Description7-Hydroxycarbostyril (3,4-Dihydro-7-hydroxycarbostyril) is a kind of pharmaceutical intermediate.
-
Description7-Hydroxycarbostyril (3,4-Dihydro-7-hydroxycarbostyril) is a kind of pharmaceutical intermediate.(In Vitro):?VPC-80051 as the first small molecule inhibitor of hnRNP A1 splicing activity discovered to date by using a computer-aided drug discovery approach. The inhibitor was developed to target the RNA-binding domain (RBD) of hnRNP A1. Further experimental evaluation demonstrated that VPC-80051 interacts directly with hnRNP A1 RBD and reduces AR-V7 messenger levels in 22Rv1 CRPC cell line. This study lays the groundwork for future structure-based development of more potent and selective small molecule inhibitors of hnRNP A1?RNA interactions aimed at altering the production of cancer-specific alternative splice isoforms.
-
In Vitro——
-
In Vivo——
-
Synonyms3,4-Dihydro-7-hydroxycarbostyril
-
PathwayOthers
-
TargetOther Targets
-
RecptorTRPA1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number70500-72-0
-
Formula Weight161.16
-
Molecular FormulaC9H7NO2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOc1ccc2ccc(O)nc2c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Cyclo(Phe-Pro)
Cyclo(Phe-Pro) known as a secondary metabolite of some bacteria and fungi, is also produced by Vibrio vulnificus.
-
Aficamten
Aficamten is a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy.
-
P110
Dynamin-related protein 1 (Drp1) inhibitor, inhibits Drp1 GTPase activity. Displays no effect on dynamin 1 or other mitochondrial dynamics-related proteins. Inhibits mitochondrial fission, dysfunction and reactive oxygen species (ROS) production in vitro. Reduces programmed cell death and improves cell viability by protecting mitochondrial integrity. Reduces mitochondrial fragmentation and mitochondrial ROS production in mouse model of Parkinson's disease. Cell permeable.
Cart
sales@molnova.com